Literature DB >> 22058013

Long-term oral administration of glucosamine or chondroitin sulfate reduces destruction of cartilage and up-regulation of MMP-3 mRNA in a model of spontaneous osteoarthritis in Hartley guinea pigs.

Shin Taniguchi1, Junnosuke Ryu, Masayuki Seki, Takanobu Sumino, Yasuaki Tokuhashi, Mariko Esumi.   

Abstract

Histological and molecular changes were examined to investigate the effects of long-term administration of glucosamine (GlcN) and chondroitin sulfate (CS) in a model of spontaneous osteoarthritis (OA) in Hartley guinea pigs. Three groups of female 3-week-old Hartley guinea pigs received GlcN, CS, and neither agent, respectively. Five animals in each group were sacrificed at 8, 12, and 18 months of age. At 8 months of age, Hartley guinea pigs had severe degeneration of knee joint cartilage, chondrocyte apoptosis, marked reduction of tissue total RNA, decreases of aggrecan and collagen type 2 mRNAs, and increases in MMP-3 and MMP-8 mRNAs. Long-term administration of GlcN and CS reduced cartilage degeneration at 8 months of age. The marked loss of total RNA and the increase in MMP-3 mRNA were also inhibited by GlcN and CS. Thus, long-term oral administration of GlcN or CS inhibits OA progression, maintains total RNA and down-regulates MMP-3 mRNA in a spontaneous OA model in Hartley guinea pigs.
Copyright © 2011 Orthopaedic Research Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22058013     DOI: 10.1002/jor.22003

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  12 in total

Review 1.  Chondroitin and glucosamine in the management of osteoarthritis: an update.

Authors:  Yves Henrotin; Cécile Lambert
Journal:  Curr Rheumatol Rep       Date:  2013-10       Impact factor: 4.592

Review 2.  Naturally Occurring Osteoarthritis Features and Treatments: Systematic Review on the Aged Guinea Pig Model.

Authors:  Francesca Veronesi; Francesca Salamanna; Lucia Martini; Milena Fini
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

Review 3.  Drug Screening Implicates Chondroitin Sulfate as a Potential Longevity Pill.

Authors:  Collin Y Ewald
Journal:  Front Aging       Date:  2021-09-08

4.  Glucosamine activates autophagy in vitro and in vivo.

Authors:  Beatriz Caramés; William B Kiosses; Yukio Akasaki; Diana C Brinson; William Eap; James Koziol; Martin K Lotz
Journal:  Arthritis Rheum       Date:  2013-07

Review 5.  Role of glucosamine in the treatment for osteoarthritis.

Authors:  Jean-Yves Reginster; Audrey Neuprez; Marie-Paule Lecart; Nathalie Sarlet; Olivier Bruyere
Journal:  Rheumatol Int       Date:  2012-03-30       Impact factor: 2.631

6.  Increased chondrocyte apoptosis is associated with progression of osteoarthritis in spontaneous Guinea pig models of the disease.

Authors:  Zaitunnatakhin Zamli; Michael A Adams; John F Tarlton; Mohammed Sharif
Journal:  Int J Mol Sci       Date:  2013-08-29       Impact factor: 5.923

Review 7.  Glucosamine and Chondroitin Sulfate: Is There Any Scientific Evidence for Their Effectiveness as Disease-Modifying Drugs in Knee Osteoarthritis Preclinical Studies?-A Systematic Review from 2000 to 2021.

Authors:  Silvia Fernández-Martín; Antonio González-Cantalapiedra; Fernando Muñoz; Mario García-González; María Permuy; Mónica López-Peña
Journal:  Animals (Basel)       Date:  2021-05-29       Impact factor: 2.752

8.  A reliable protocol for the isolation of viable, chondrogenically differentiated human mesenchymal stem cells from high-density pellet cultures.

Authors:  Mujib Ullah; Houda Hamouda; Stefan Stich; Michael Sittinger; Jochen Ringe
Journal:  Biores Open Access       Date:  2012-12

9.  A review of translational animal models for knee osteoarthritis.

Authors:  Martin H Gregory; Nicholas Capito; Keiichi Kuroki; Aaron M Stoker; James L Cook; Seth L Sherman
Journal:  Arthritis       Date:  2012-12-27

Review 10.  On the predictive utility of animal models of osteoarthritis.

Authors:  Anne-Marie Malfait; Christopher B Little
Journal:  Arthritis Res Ther       Date:  2015-09-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.